The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC. The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data. The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery. The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC. The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading. The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients. The panel shared their excitement for the road ahead in kidney cancer. The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment. The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan. The panel discussed the impact of a subcutaneous formulation of nivolumab. The panel discussed the role of SBRT and some exciting studies like SAMURAI. The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab. The panel shared their thoughts on the 8-year follow-up data from CheckMate 214. The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914. The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more. The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab. The panel highlighted the CheckMate 9ER study and implications for clinical practice. The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria. The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice. The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.